PROTOCOL OF THE HYPERTENSION THERAPY WITH IRBESARTAN VERSUS EPLERENONE FOR OBESE HYPERTENSIVE PATIENTS (HEBRO): A RANDOMIZED CLINICAL TRIAL

P Iliakis,Costas Tsioufis,Emmanuel A. Andreadis,Stella Douma,Michalis Doumas,Kyriakos Dimitriadis,C. Grassos,Apostolos I. Hatzitolios,R. Kalaitzidis,Dimitris Konstantinidis,Vasilis Kotsis,Th. Makris,M. Marketou,Efstathios Manios,I. Papadakis,D. Papadopoulos,Athanassios D. Protogerou,G.S. Stergiou,Costas Thomopoulos,Helen Triantafyllidi,Demetrios V. Vlahakos,Pantelis Zebekakis,Dimitrios Tousoulis

PROTOCOL OF THE HYPERTENSION THERAPY WITH IRBESARTAN VERSUS EPLERENONE FOR OBESE HYPERTENSIVE PATIENTS (HEBRO): A RANDOMIZED CLINICAL TRIAL

2019

Objective:Hypertension and obesity often coexist and activation of the renin-angiotensin- aldosterone (RAS) axis plays a major pathophysiological role. Since obese hypertensive patients are less frequently controlled within-goal compared with hypertensives without obesity, we aimed to determine whet

Keywords:

Randomized controlled trial
Irbesartan
Endocrinology
Diabetes mellitus
Eplerenone
Internal medicine
Medicine
Pathophysiology
Aldosterone
Obesity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations